Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone

Clin Pharmacol Ther. 2007 Jul;82(1):48-53. doi: 10.1038/sj.clpt.6100164. Epub 2007 Mar 28.

Abstract

Peripheral mechanisms may be involved in opioid actions on the urinary bladder. This double-blind study investigated whether opioid inhibition of bladder function is reversed by methylnaltrexone, a peripheral opioid antagonist. Thirteen healthy male volunteers received an intravenous (i.v.) infusion of remifentanil, 0.15 mcg/kg/min, then a single i.v. dose of study medication (methylnaltrexone 0.3 mg/kg, naloxone 0.01 mg/kg, or saline). Urodynamics were measured with indwelling bladder and rectal catheters, and pupil size was assessed with infrared pupillometry. Remifentanil decreased detrusor pressure in 21/25 sessions and caused complete urinary retention in 18/25. Voiding was possible in 7/7, 5/12, and 0/6 sessions after naloxone, methylnaltrexone, and saline, respectively (P=0.0013). Remifentanil caused marked miosis that was reversed by naloxone, but not methylnaltrexone or placebo (P<0.0001). The pupil data confirm that methylnaltrexone did not reverse central opioid effects. Reversal of urinary retention by methylnaltrexone indicates that peripheral mechanisms may play a role in opioid-induced bladder dysfunction.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / adverse effects*
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Miosis / chemically induced
  • Miosis / drug therapy
  • Muscle Contraction / drug effects
  • Naloxone / administration & dosage
  • Naloxone / therapeutic use*
  • Naltrexone / administration & dosage
  • Naltrexone / analogs & derivatives*
  • Naltrexone / therapeutic use
  • Narcotic Antagonists / administration & dosage
  • Narcotic Antagonists / therapeutic use*
  • Piperidines / administration & dosage
  • Piperidines / adverse effects*
  • Quaternary Ammonium Compounds / administration & dosage
  • Quaternary Ammonium Compounds / therapeutic use
  • Remifentanil
  • Treatment Outcome
  • Urinary Bladder / drug effects*
  • Urinary Bladder / physiopathology
  • Urinary Retention / chemically induced
  • Urinary Retention / drug therapy*
  • Urinary Retention / physiopathology
  • Urination / drug effects

Substances

  • Analgesics, Opioid
  • Narcotic Antagonists
  • Piperidines
  • Quaternary Ammonium Compounds
  • methylnaltrexone
  • Naloxone
  • Naltrexone
  • Remifentanil